Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 30,900 shares, a drop of 18.9% from the November 15th total of 38,100 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Bio-Path in a research report on Tuesday. They issued a “sell” rating for the company.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Stock Down 5.6 %

Shares of BPTH traded down $0.04 during trading hours on Friday, reaching $0.66. 44,957 shares of the stock traded hands, compared to its average volume of 1,059,295. The company’s 50-day moving average price is $0.90 and its two-hundred day moving average price is $1.35. Bio-Path has a 52-week low of $0.59 and a 52-week high of $12.00.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.